Ultralife Q3 2026 earnings turn to $2.4M profit

Ultralife's backlog reached $136.0 million, while its agreed all-cash acquisition by EnerSys is expected to close in the first quarter of 2027.

Available on EDGAR 11/09/2026 - 03:38 PM EST Accepted by SEC EDGAR 11/09/2026 - 03:37 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ultralife Corporation reported third-quarter 2026 sales of $48.3 million, up 11.3% from $43.4 million a year earlier. Gross profit was $13.3 million, or 27.5% of sales, compared with $9.6 million and 22.2%. Operating income was $3.2 million versus a $1.0 million loss; net income attributable to Ultralife was $2.4 million versus a $1.2 million loss, and GAAP earnings were $0.14 per share versus a loss of $0.07 per share. Adjusted EBITDA, a non-GAAP measure, was $5.6 million versus $2.0 million. Backlog reached a company-record $136.0 million, versus $117.5 million exiting the second quarter and $90.3 million a year earlier.

Battery & Energy Products sales rose 12.9% to $45.1 million, while Communications Systems sales fell 7.1% to $3.2 million. Government/defense sales increased 56.7%, primarily reflecting a large conformal wearable battery order; commercial sales declined 5.8%, primarily due to softness in the global oil and gas market. On October 27, 2026, Ultralife announced an agreement to be acquired by EnerSys in an all-cash transaction valued at approximately $320 million, including assumption of net debt. The transaction is expected to close in the first quarter of 2027.

3 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

How the balance works

Positive

• Moderate pointThird-quarter revenue rose 11.3% to $48.3 million.
• Moderate pointOperating income was $3.2 million, versus a $1.0 million loss.
• Minor pointAdjusted EBITDA reached $5.6 million, compared with $2.0 million.

Negative

• Minor pointCommunications Systems sales fell 7.1% to $3.2 million.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Revenue: $48.3 million Gross margin: 27.5% Operating income: $3.2 million +4 more

7 metrics

Revenue $48.3 million Third quarter 2026; up 11.3% from $43.4 million in third quarter 2025

Gross margin 27.5% Third quarter 2026; 22.2% in third quarter 2025

Operating income $3.2 million Third quarter 2026; compared with a $1.0 million operating loss in third quarter 2025

Net income attributable to Ultralife $2.4 million Third quarter 2026; compared with a $1.2 million loss in third quarter 2025

Adjusted EBITDA $5.6 million Non-GAAP measure; third quarter 2026, compared with $2.0 million in third quarter 2025

Backlog $136.0 million Exiting third quarter 2026; highest in company history

Transaction value Approximately $320 million Agreed all-cash acquisition by EnerSys, including assumption of net debt; expected to close in first quarter 2027

Key Terms

Adjusted EBITDA, 45X Advanced Manufacturing Production Tax Credit, vertical integration, backlog

4 terms

Adjusted EBITDA financial

"Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

45X Advanced Manufacturing Production Tax Credit regulatory

"refundable tax credit for certain qualifying battery cells and packs"

A 45x advanced manufacturing production tax credit is a government incentive that gives manufacturers a fixed tax benefit for each eligible unit they produce of certain advanced products, effectively acting like a per-item rebate on production. It matters to investors because it increases a producer’s after-tax profit and can lower break-even costs—similar to getting a discount on materials—making companies more competitive, improving margins, and potentially raising future cash flow and valuation.

vertical integration technical

"vertical integration of our thionyl-chloride cells"

Vertical integration occurs when a company controls multiple stages of its production or supply chain, such as making its own products and also distributing or selling them. This can help the company reduce costs and increase control over quality and delivery. For investors, it often signals a company’s effort to become more self-sufficient and competitive in its industry.

backlog financial

"Our total backlog exiting the third quarter was $136.0 million"

A backlog is the amount of work or orders that a company has received but hasn't completed yet. It’s like a restaurant with many dishes to serve; the backlog shows how many orders are still waiting to be finished. It matters because a large backlog can indicate strong demand or potential delays in delivering products or services.

Earnings Snapshot

Revenue: $48.3 million

Third quarter ended September 30, 2026

Revenue $48.3 million 11.3% increase from $43.4 million

Gross margin 27.5% Compared with 22.2%

Operating income $3.2 million Compared with a $1.0 million operating loss

GAAP earnings per share $0.14 per basic and diluted share Compared with a loss of $0.07 per basic and diluted share

Adjusted EBITDA $5.6 million Compared with $2.0 million

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were ULBI's third-quarter sales and earnings?

ULBI reported third-quarter sales of $48.3 million, up 11.3% from $43.4 million, and net income attributable to Ultralife of $2.4 million versus a $1.2 million loss. GAAP earnings were $0.14 per basic and diluted share, compared with a loss of $0.07 per share.

What was ULBI's backlog at the end of the third quarter?

Ultralife reported backlog of $136.0 million exiting the third quarter, the highest level in company history. Backlog was $117.5 million exiting the second quarter of 2026 and $90.3 million exiting the third quarter of 2025.

When is ULBI's acquisition by EnerSys expected to close?

Ultralife's agreed all-cash acquisition by EnerSys, valued at approximately $320 million including assumption of net debt, is expected to close in the first quarter of 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0000875657 0000875657 2026-11-05 2026-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 5, 2026

Date of Report (Date of Earliest Event Reported)

ULTRALIFE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	000-20852	16-1387013
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2000 Technology Parkway, Newark, New York 14513

(Address of principal executive offices) (Zip Code)

(315) 332-7100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.10 par value per share		ULBI		NASDAQ Stock Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On November 5, 2026, Ultralife Corporation issued a press release regarding the financial results for its third quarter ended September 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

Item 9.01 Financial Statements, Pro Forma Financials and Exhibits

(d) Exhibits.

Exhibit Number		Exhibit Description
99.1		Press Release of Ultralife Corporation dated November 5, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 9, 2026		ULTRALIFE CORPORATION
	By:	/s/ Philip A. Fain
		Philip A. Fain
		Chief Financial Officer and Treasurer

Exhibit 99.1

Ultralife Corporation Reports Third Quarter Results

NEWARK, N.Y. – November 5, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2026 with the following results:

	●	Sales of $48.3 million compared to $43.4 million for the 2025 third quarter
	●	Gross profit of $13.3 million, or 27.5% of revenue, compared to $9.6 million, or 22.2% of revenue, for the 2025 third quarter
	●	Operating income of $3.2 million compared to an operating loss of $1.0 million for the 2025 third quarter
	●	GAAP EPS of $0.14 compared to ($0.07) for the 2025 third quarter
	●	Adjusted EBITDA of $5.6 million compared to $2.0 million for the 2025 third quarter
	●	Backlog of $136.0 million compared to $117.5 million exiting the second quarter of 2026

On October 27, 2026, Ultralife announced that it has agreed to be acquired by EnerSys (NYSE: ENS) in an all-cash transaction valued at approximately $320 million, including the assumption of net debt.  The transaction is expected to close in the first quarter of 2027.  In light of this pending transaction, Ultralife will not hold a conference call to discuss third quarter results. 

Third Quarter 2026 Financial Results

Revenue was $48.3 million, an increase of $4.9 million, or 11.3%, as compared to revenue of $43.4 million for the third quarter of 2025. Battery & Energy Products sales increased 12.9% to $45.1 million compared to $39.9 million last year. The year-over-year increase reflects 56.7% growth in government/defense sales due primarily to a large order for conformal wearable batteries, partially offset by 5.8% decrease in commercial sales primarily due to softness in the global oil & gas market. Communications Systems sales decreased by 7.1% to $3.2 million compared to $3.4 million for the same period last year. Our total backlog exiting the third quarter was $136.0 million, the highest level in the Company’s history, compared to $117.5 million exiting the second quarter of 2026 and $90.3 million exiting the third quarter of 2025.

Gross profit was $13.3 million, or 27.5% of revenue, compared to $9.6 million, or 22.2% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 26.7%, compared to 22.1% last year, primarily due to progress in improving manufacturing efficiencies and vertical integration of our thionyl-chloride cells as well as favorable product mix. Communications Systems gross margin was 40.1% compared to 23.3% last year, primarily due to lower warranty costs and sales mix.

Operating expenses were $10.1 million, compared to $10.6 million for the third quarter of 2025, reflecting an increase in new product development costs related to continued investment in our product offering, and a decrease in one-time, non-recurring costs of $0.6 million primarily related to the closing of our Calgary facility and certain consulting costs to help expedite our gross margin improvement in the year-earlier period. Operating expenses were 20.9% of revenue compared to 24.4% of revenue for the year-earlier period.

Operating income was $3.2 million compared to an operating loss of $1.0 million last year.

Other expense was $0.4 million primarily comprised of interest expense from the financing of our Electrochem acquisition partially offset by the third quarter estimated portion of a refundable tax credit for certain qualifying battery cells and packs we manufacture under the 45X Advanced Manufacturing Production Tax Credit. This compares to $0.8 million for the year-earlier period primarily reflecting the Electrochem acquisition financing and net foreign currency gains.

Net income attributable to Ultralife Corporation was $2.4 million or $0.14 per basic and diluted share on a GAAP basis, compared to a net loss of ($1.2) million or ($0.07) per basic and diluted share for the third quarter of 2025.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense and one-time costs not reflective of our ongoing operations, was $5.6 million for the third quarter of 2026, or 11.7% of sales, compared to $2.0 million, or 4.7% of sales, for the year-earlier period. On a trailing twelve-month basis, adjusted EBITDA was $20.7 million or 10.8% of sales.

See the “Non-GAAP Financial Measures” section of this release below for a reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation is a global leader in mission-critical battery, power, communications and compute solutions for the most demanding applications in government/defense, medical, oil & gas and industrial markets across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions including the impact of tariffs and inflation, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions, delays or material price increases in our supply of raw materials and components due to business conditions, new or additional tariffs, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands)

(Unaudited)

​	​	September 30,		​	​	December 31,		​
​	​	2026		​	​	2025		​
ASSETS
Current Assets:	​	​	​	​	​	​	​	​
Cash	​		$8,628	​	​		$9,345	​
Trade Accounts Receivable, Net	​	​	35,790	​	​	​	33,948	​
Inventories, Net	​	​	62,314	​	​	​	54,008	​
Prepaid Expenses and Other Current Assets	​	​	9,914	​	​	​	8,500	​
Total Current Assets	​	​	116,646	​	​	​	105,801	​
​	​	​	​	​	​	​	​	​
Property, Plant and Equipment, Net	​	​	39,011	​	​	​	40,397	​
Goodwill	​	​	45,403	​	​	​	45,376	​
Other Intangible Assets, Net	​	​	10,121	​	​	​	10,933	​
Deferred Income Taxes, Net	​	​	10,029	​	​	​	10,494	​
Other Non-Current Assets	​	​	3,193	​	​	​	3,911	​
Total Assets	​	​	$224,403	​	​		$216,912	​
​	​	​	​	​	​	​	​	​
LIABILITIES AND SHAREHOLDERS' EQUITY								​
​	​	​	​	​	​	​	​	​
Current Liabilities:	​	​	​	​	​	​	​	​
Accounts Payable	​		$19,581	​	​		$17,423	​
Current Portion of Long-Term Debt	​	​	3,125	​	​	​	4,125	​
Accrued Compensation and Related Benefits	​	​	2,941	​	​	​	2,754	​
Accrued Expenses and Other Current Liabilities	​	​	13,673	​	​	​	13,031	​
Total Current Liabilities	​	​	39,320	​	​	​	37,333	​
Long-Term Debt, Net	​	​	47,393	​	​	​	45,526	​
Deferred Income Taxes, Net	​	​	897	​	​	​	1,000	​
Other Non-Current Liabilities	​	​	2,156	​	​	​	2,919	​
Total Liabilities	​	​	89,766	​	​	​	86,778	​
​	​	​	​	​	​	​	​	​
Shareholders' Equity:	​	​	​	​	​	​	​	​
Common Stock	​	​	2,110	​	​	​	2,109	​
Capital in Excess of Par Value	​	​	193,081	​	​	​	192,859	​
Accumulated Deficit	​	​	(35,880)		​	​	(40,340)
Accumulated Other Comprehensive Loss	​	​	(3,291)		​	​	(3,141)
Treasury Stock	​	​	(21,492)		​	​	(21,492)
Total Ultralife Equity	​	​	134,528	​	​	​	129,995	​
Non-Controlling Interest	​	​	109	​	​	​	139	​
Total Shareholders’ Equity	​	​	134,637	​	​	​	130,134	​
​	​	​	​	​	​	​	​	​
Total Liabilities and Shareholders' Equity	​		$224,403	​	​		$216,912	​

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In Thousands Except Per Share Amounts)

(Unaudited) 

​

​

Three-Month Period Ended

​

​

Nine-Month Period Ended

​

​

​

September

​

​

September

​

​

September

​

​

September

​

​

​

30,

​

​

30,

​

​

30,

​

​

30,

​

​

​

2026

​

​

2025

​

​

2026

​

​

2025

​

Revenues:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Battery & Energy Products

​

$45,089

​

​

$39,946

​

​

$133,433

​

​

$132,134

​

Communications Systems

​

​

3,182

​

​

​

3,425

​

​

​

10,226

​

​

​

10,544

​

Total Revenues

​

​

48,271

​

​

​

43,371

​

​

​

143,659

​

​

​

142,678

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Cost of Products Sold:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Battery & Energy Products

​

​

33,071

​

​

​

31,126

​

​

​

99,554

​

​

​

101,039

​

Communications Systems

​

​

1,907

​

​

​

2,626

​

​

​

6,836

​

​

​

7,674

​

Total Cost of Products Sold

​

​

34,978

​

​

​

33,752

​

​

​

106,390

​

​

​

108,713

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Gross Profit

​

​

13,293

​

​

​

9,619

​

​

​

37,269

​

​

​

33,965

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Operating Expenses:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Research and Development

​

​

3,189

​

​

​

2,855

​

​

​

9,375

​

​

​

7,577

​

Selling, General and Administrative

​

​

6,918

​

​

​

7,715

​

​

​

21,486

​

​

​

21,684

​

Total Operating Expenses

​

​

10,107

​

​

​

10,570

​

​

​

30,861

​

​

​

29,261

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Operating Income (Loss)

​

​

3,186

​

​

​

(951)

​

​

​

6,408

​

​

​

4,704

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Other Expense

​

​

441

​

​

​

800

​

​

​

1,340

​

​

​

2,896

​

Income (Loss) Before Income Taxes

​

​

2,745

​

​

​

(1,751)

​

​

​

5,068

​

​

​

1,808

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Income Tax Provision (Benefit)

​

​

362

​

​

​

(504)

​

​

​

638

​

​

​

306

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net Income (Loss)

​

​

2,383

​

​

​

(1,247)

​

​

​

4,430

​

​

​

1,502

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net Income (Loss) Attributable to Non-Controlling Interest

​

​

15

​

​

​

(27)

​

​

​

(30)

​

​

​

(22)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net Income (Loss) Attributable to Ultralife Corporation

​

$2,368

​

​

$(1,220)

​

$4,460

​

​

$1,524

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net Income (Loss) Per Share Attributable to Ultralife Common Shareholders – Basic

​

$0.14

​

​

$(0.07)

​

$0.27

​

​

$0.09

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net Income (Loss) Per Share Attributable to Ultralife Common Shareholders – Diluted

​

$0.14

​

​

$(0.07)

​

$0.27

​

​

$0.09

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted Average Shares Outstanding – Basic

​

​

16,664

​

​

​

16,646

​

​

​

16,660

​

​

​

16,638

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted Average Shares Outstanding – Diluted

​

​

16,697

​

​

​

16,646

​

​

​

16,703

​

​

​

16,699

​

Non-GAAP Financial Measures

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EBITDA

(Dollars in Thousands)

(Unaudited)

​

​

Three-Month Period Ended

​

​

Nine-Month Period Ended

​

​

​

September 30, 2026

​

​

September 30, 2025

​

​

September 30, 2026

​

​

September 30, 2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Net Income (Loss) Attributable to Ultralife Corporation

​

$2,368

​

​

​

(1,220)

​

$4,460

​

​

$1,524

​

Adjustments:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Interest Expense, Net

​

​

921

​

​

​

992

​

​

​

2,628

​

​

​

3,016

​

Income Tax Provision (Benefit)

​

​

362

​

​

​

(504)

​

​

638

​

​

​

306

​

Depreciation Expense

​

​

1,098

​

​

​

1,008

​

​

​

3,208

​

​

​

2,966

​

Amortization Expense

​

​

267

​

​

​

411

​

​

​

802

​

​

​

1,226

​

Stock-Based Compensation Expense

​

​

92

​

​

​

236

​

​

​

181

​

​

​

698

​

Other Non-Recurring Costs

​

​

278

​

​

​

594

​

​

​

2,009

​

​

​

1,112

​

One-Time Events Impacting Production

​

​

250

​

​

​

-

​

​

​

1,067

​

​

​

-

​

Severance and Other Costs for Plant Closure

​

​

-

​

​

​

491

​

​

​

-

​

​

​

641

​

Non-Cash Purchase Accounting Adjustment

​

​

-

​

​

​

40

​

​

​

-

​

​

​

120

​

Adjusted EBITDA

​

$5,636

​

​

$2,048

​

​

$14,993

​

​

$11,609

​

Company Contact:

Ultralife Corporation

Philip A. Fain

(315) 210-6110

pfain@ulbi.com

Investor Relations Contact:

Alliance Advisors IR

Jody Burfening

(212) 838-3777

jburfening@allianceadvisors.com

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 322.6 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.2 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.3 KB